FDA issues a safety alert on unsafe counterfeit versions of AbbVie’s Botox (botulinum toxin) have been found in multiple states and administered to consumers for cosmetic purposes.
FDA warns Soulaire Corp. that it is marketing an external counterpulsation system for unapproved uses, adulterating and misbranding the unit.
FDA issues a safety alert on unsafe counterfeit versions of AbbVie’s Botox (botulinum toxin) have been found in multiple states and administered to consumers for cosmetic purposes.
FDA warns Soulaire Corp. that it is marketing an external counterpulsation system for unapproved uses, adulterating and misbranding the unit.
FDA warns the Telangana, India-based Natco Pharma manufacturing facility about CGMP violations in its production of finished drugs.
CDER establishes the Center for Clinical Trial Innovation to support innovative approaches to clinical trials that are designed to improve the quality and efficiency of drug development.
